Leerink Partnrs Issues Positive Estimate for ACAD Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Investment analysts at Leerink Partnrs lifted their Q2 2025 EPS estimates for ACADIA Pharmaceuticals in a research note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings of $0.21 per share for the quarter, up from their previous estimate of $0.17. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals' Q4 2025 earnings at $0.17 EPS, FY2026 earnings at $0.65 EPS, FY2027 earnings at $1.05 EPS and FY2028 earnings at $1.75 EPS.

A number of other brokerages also recently weighed in on ACAD. Deutsche Bank Aktiengesellschaft began coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a "hold" rating and a $22.00 price target for the company. Cantor Fitzgerald restated an "overweight" rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. StockNews.com upgraded shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, March 8th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $20.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Friday, March 7th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Tuesday, April 8th. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $23.93.

ACADIA Pharmaceuticals Price Performance

Shares of NASDAQ ACAD traded up $0.16 during mid-day trading on Tuesday, reaching $14.73. 1,208,871 shares of the company traded hands, compared to its average volume of 1,851,308. ACADIA Pharmaceuticals has a fifty-two week low of $13.40 and a fifty-two week high of $20.68. The stock has a fifty day simple moving average of $17.16 and a 200-day simple moving average of $16.94. The firm has a market cap of $2.46 billion, a PE ratio of 18.88 and a beta of 0.54.

Insiders Place Their Bets

In other news, EVP Mark C. Schneyer sold 3,171 shares of the business's stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total value of $54,065.55. Following the completion of the sale, the executive vice president now directly owns 56,889 shares in the company, valued at approximately $969,957.45. The trade was a 5.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the transaction, the director now owns 17,595 shares in the company, valued at $320,756.85. This trade represents a 21.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,169 shares of company stock valued at $242,686 over the last quarter. Insiders own 28.30% of the company's stock.

Institutional Trading of ACADIA Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ACAD. Exchange Traded Concepts LLC acquired a new stake in ACADIA Pharmaceuticals during the first quarter worth about $29,000. Virtus Fund Advisers LLC acquired a new position in shares of ACADIA Pharmaceuticals in the fourth quarter valued at $39,000. R Squared Ltd bought a new position in ACADIA Pharmaceuticals in the fourth quarter worth $47,000. GAMMA Investing LLC boosted its stake in ACADIA Pharmaceuticals by 627.3% during the first quarter. GAMMA Investing LLC now owns 3,513 shares of the biopharmaceutical company's stock worth $58,000 after buying an additional 3,030 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in ACADIA Pharmaceuticals in the 4th quarter valued at $64,000. 96.71% of the stock is currently owned by institutional investors and hedge funds.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.